文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气消化、代谢与肾脏急症

美国全国COVID-19患者院内死亡风险因素分析

Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19.
PubMed 文献 · JAMA Netw Open · 2020-12-01

住院患者院内死亡率20.3%,15.9%接受有创机械通气,19.4%入住ICU;常见急性并发症为急性呼吸衰竭55.8%、急性肾衰竭33.9%、脓毒症33.7%。年龄≥80岁较18-34岁死亡风险显著升高(OR 16.20,95%CI 11.58-22.67)。他汀、ACEI、CCB使用与死亡风险降低相关,羟氯喹联合阿奇霉素与死亡风险升高相关(OR 1.21)。上述药物关联需前瞻性随机试验验证。

要点

  • 年龄≥80岁较18-34岁死亡风险大幅升高(OR 16.20,95%CI 11.58-22.67,P<.001),为关联最强风险因素。
  • 他汀(OR 0.60,95%CI 0.56-0.65)、ACEI(OR 0.53,95%CI 0.46-0.60)、CCB(OR 0.73,95%CI 0.68-0.79)使用与死亡风险降低相关。
  • 羟氯喹联合阿奇霉素较两者均未使用与死亡风险升高相关(OR 1.21,95%CI 1.11-1.31,P<.001)。
  • 住院患者中急性呼吸衰竭55.8%、急性肾衰竭33.9%、脓毒症33.7%为最常见急性并发症。

适用人群与场景

  • 住院患者中位年龄65岁(IQR 52-77),门诊患者中位年龄46岁(IQR 33-59)。

诊断标准与关键阈值

  • COVID-19诊断依据ICD-10-CM诊断编码U07.1(主要或次要出院诊断)。
  • 原文未提及ICU入住、有创机械通气启动或停止的具体阈值标准。

处置流程与药物剂量

  • 原文未提及具体的处置流程或药物剂量方案;仅报告了药物使用与死亡风险的关联,非治疗推荐。
  • 他汀使用与死亡风险降低相关(OR 0.60,95%CI 0.56-0.65),原文未报告具体药物、剂量、途径及疗程。
  • ACEI使用与死亡风险降低相关(OR 0.53,95%CI 0.46-0.60),原文未报告具体药物、剂量、途径及疗程。
  • CCB使用与死亡风险降低相关(OR 0.73,95%CI 0.68-0.79),原文未报告具体药物、剂量、途径及疗程。
  • 羟氯喹联合阿奇霉素使用与死亡风险升高相关(OR 1.21,95%CI 1.11-1.31),原文未报告具体剂量、途径及疗程。

红旗征与不能漏的情况

  • 高龄(≥80岁较18-34岁死亡OR 16.20,95%CI 11.58-22.67)为需警惕的高死亡风险人群。
  • 住院期间出现急性呼吸衰竭(55.8%)、急性肾衰竭(33.9%)或脓毒症(33.7%)提示病情危重。
  • 需要有创机械通气(15.9%)或入住ICU(19.4%)提示重症。

研究设计与关键结果

  • 研究类型:回顾性队列研究,基于Premier Healthcare Database,纳入美国592家急性照护医院。
  • 主要终点:住院患者院内死亡率为20.3%(7164例)。
  • 次要终点:15.9%住院患者接受有创机械通气,19.4%入住ICU;住院中位LOS 6天(IQR 3-10),ICU中位LOS 5天(IQR 2-10)。
  • 常见急性并发症:急性呼吸衰竭55.8%、急性肾衰竭33.9%、脓毒症33.7%。
  • 风险因素:年龄≥80岁 vs 18-34岁死亡OR 16.20(95%CI 11.58-22.67,P<.001);他汀OR 0.60(95%CI 0.56-0.65,P<.001);ACEI OR 0.53(95%CI 0.46-0.60,P<.001);CCB OR 0.73(95%CI 0.68-0.79,P<.001);羟氯喹联合阿奇霉素 vs 两者均无 OR 1.21(95%CI 1.11-1.31,P<.001)。
  • 原文未报告关键次要终点的组间比较效应量及不良事件数据。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(基于行政数据库)。
  • 局限:原文未明确列出局限;设计本身为回顾性、观察性、基于行政编码数据库,药物使用与死亡风险的关联可能受适应证混杂影响,不能推断因果。

对床旁实践的改变

  • 该研究提示高龄(尤其≥80岁)COVID-19住院患者死亡风险显著升高,床旁应加强风险评估与监护。
  • 他汀、ACEI、CCB使用与死亡风险降低相关,但为观察性关联,不能据此在ICU常规启动这些药物用于降低COVID-19死亡风险。
  • 羟氯喹联合阿奇霉素与死亡风险升高相关,支持避免该联合方案用于COVID-19治疗。
  • 原文未提及对急诊/ICU具体处置流程的改变;适用与不适用人群、常见陷阱原文未专门讨论。

指南或共识出处

  • 原文未提及指南或共识出处;本文为研究论文(JAMA Netw Open)。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Coronavirus disease 2019 (COVID-19) has infected more than 8.1 million US residents and killed more than 221 000. There is a dearth of research on epidemiology and clinical outcomes in US patients with COVID-19.

OBJECTIVES: To characterize patients with COVID-19 treated in US hospitals and to examine risk factors associated with in-hospital mortality.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted using Premier Healthcare Database, a large geographically diverse all-payer hospital administrative database including 592 acute care hospitals in the United States. Inpatient and hospital-based outpatient visits with a principal or secondary discharge diagnosis of COVID-19 (International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis code, U07.1) between April 1 and May 31, 2020, were included.

EXPOSURES: Characteristics of patients were reported by inpatient/outpatient and survival status. Risk factors associated with death examined included patient characteristics, acute complications, comorbidities, and medications.

MAIN OUTCOMES AND MEASURES: In-hospital mortality, intensive care unit (ICU) admission, use of invasive mechanical ventilation, total hospital length of stay (LOS), ICU LOS, acute complications, and treatment patterns.

RESULTS: Overall, 64 781 patients with COVID-19 (29 479 [45.5%] outpatients; 35 302 [54.5%] inpatients) were analyzed. The median (interquartile range [IQR]) age was 46 (33-59) years for outpatients and 65 (52-77) years for inpatients; 31 968 (49.3%) were men, 25 841 (39.9%) were White US residents, and 14 340 (22.1%) were Black US residents. In-hospital mortality was 20.3% among inpatients (7164 patients). A total of 5625 inpatients (15.9%) received invasive mechanical ventilation, and 6849 (19.4%) were admitted to the ICU. Median (IQR) inpatient LOS was 6 (3-10) days. Median (IQR) ICU LOS was 5 (2-10) days. Common acute complications among inpatients included acute respiratory failure (19 706 [55.8%]), acute kidney failure (11 971 [33.9%]), and sepsis (11 910 [33.7%]). Older age was the risk factor most strongly associated with death (eg, age ≥80 years vs 18-34 years: odds ratio [OR], 16.20; 95% CI, 11.58-22.67; P < .001). Receipt of statins (OR, 0.60; 95% CI, 0.56-0.65; P < .001), angiotensin-converting enzyme inhibitors (OR, 0.53; 95% CI, 0.46-0.60; P < .001), and calcium channel blockers (OR, 0.73; 95% CI, 0.68-0.79; P < .001) was associated with decreased odds of death. Compared with patients with no hydroxychloroquine or azithromycin, patients with both azithromycin and hydroxychloroquine had increased odds of death (OR, 1.21; 95% CI, 1.11-1.31; P < .001).

CONCLUSIONS AND RELEVANCE: In this cohort study of patients with COVID-19 infection in US acute care hospitals, COVID-19 was associated with high ICU admission and in-hospital mortality rates. Use of statins, angiotensin-converting enzyme inhibitors, and calcium channel blockers were associated with decreased odds of death. Understanding the potential benefits of unproven treatments will require future randomized trials.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Rosenthal N, Cao Z, Gundrum J, et al. Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19. JAMA Netw Open. 2020. PMID: 33301018. doi:10.1001/jamanetworkopen.2020.29058

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。